CV-06 / Cellivery, Ildong - LARVOL DELTA

Cellivery Announces Brain Transmission Capability New Drug for Degenerative Brain Disease at International Conference [Google translation] (The Korea Economic Daily) - "Cellivery announced on the 23rd that it had announced the research results of 'iCP-Parkin'...the Alzheimer's disease/Parkinson's disease international conference (AD/PDTM 2022)....At this event, Cellivery made a total of three iCP-Parkin related presentations. When iCP-Parkin was injected intravenously, it provided evidence that it penetrates the blood-brain barrier (BBB) ​​(permeability rate of 5.6%)...In Parkinson's disease (PD), the second degenerative brain disease, it effectively removes α-synuclein, a disease-causing protein aggregate, to restore the motor ability of Parkinson's disease by 92%."

Preclinical • CNS Disorders • Parkinson's Disease

A BRAIN-DELIVERABLE PARKIN PROTECTS NEURONS BY SUPPRESSING ACCUMULATION OF DAMAGED MITOCHONDRIA AND PATHOLOGICAL Α-SYNUCLEIN (ADPD 2022) - "Based on these outcomes, iCP-Parkin has a great therapeutic potential as a PD-modifying agent with superior productivity."

CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Targeted Protein Degradation

BRAIN DELIVERY OF PARKIN WITH CELL-PERMEABILITY REDUCES AGGREGATED Β-AMYLOID AND RECOVERS COGNITIVE FUNCTION IN FIBRIL Β-AMYLOID-INDUCED ANIMALS (ADPD 2022) - "In conclusion, the present outcome evidently supports the ability of iCP-Parkin to remove Aβ plaques and recover from cognitive dysfunction with mitochondria recovery, demonstrating its potential as a novel therapeutic agent against AD."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Metabolic Disorders

Cellivery receives proposals for joint clinical development from global pharmaceutical companies at '2022 Biotech Showcase' [Google translation] (Money Today Network (MTN)) - "After the JP Morgan Healthcare Conference in the US, Cellivery participated in 'Biotech Showcase 2022', a partnering event specializing in investment in the life science field, and held active partnering meetings with a total of 22 global pharmaceutical and bio companies and venture capitalels (VCs)....The company mentioned that it has taken an active stance on pipeline licensing other than iCP-NI and Parkinson's disease treatment 'iCP-Parkin', which are currently under licensing discussion....Confirmed the blood brain barrier (BBB) ​​penetrability data (5.6%) of iCP-Parkin, and then developed a TSDT platform for the degenerative brain disease treatment that it is developing."

Licensing / partnership • Preclinical • CNS Disorders • Parkinson's Disease

Cellibury Announces Current Status of New Concept Corona Treatment at JP Morgan Health Conference [Google translation] (BioTimes) - "Cellevery will present efficacy data on the dementia treatment iCP-Parkin at this conference. Introducing TSDT, a proprietary platform technology, and using this platform technology, iCP- a dementia treatment drug that can restore cognitive loss caused by degenerative brain diseases (Alzheimer's disease and Parkinson's disease) under development. Efficacy data for Parkin are also published....'We look forward to entering into new contracts with global pharmaceutical companies and new partners.'"

Preclinical • CNS Disorders • Parkinson's Disease

Sellybury requests due diligence for L/O from global pharmaceutical companies at 'Bio Europe' event [Google translation] (Pax Economic TV) - "Regarding the licensing of iCP-Parkin...the partnering headquarters of Orion (Finland), a Nordic pharmaceutical company, said, 'The negotiations have been delayed due to the revision of Corona 19 and Orion's R&D strategy. He said he hoped, 'We hope to proceed as soon as possible with the Dew Diligence as reprinted with the licensing deal, including the material transfer contract, as previously discussed.'"

Licensing / partnership • CNS Disorders • Parkinson's Disease

Sellyvery, exclusive meeting with 10 global pharmaceutical companies at Asia's largest business partnership 'Bio Japan' [Google translation] (Money Today Co., Ltd) - "...New therapeutic efficacy data for dementia and Alzheimer's disease of iCP-Parkin, a new drug for degenerative brain disease treatment, was announced for Lundbeck, a specialist in neurological disorders. In the animal model of Alzheimer's disease caused by the disease, iCP-Parkin showed 101% cognitive function recovery effect compared to the control group. iCP-Parkin's effects are only shown not in Parkinson's disease, but even more extensively in Alzheimer's."

Preclinical • Alzheimer's Disease • CNS Disorders • Parkinson's Disease

Parkinson's disease, challenge to develop various treatments despite successive failures [Google translation] (BioTimes) - "ICP-Parkin (improved cell-permeable Parkin), which Cellevery is developing, is a candidate drug that reduces the accumulation of alpha-synuclein, and is under the sponsorship of the Michael J. Fox Foundation (MJFF) in joint research with Ildong Pharmaceutical. to be....A company official said, 'We recently raised 44 billion of capital, which we plan to use for non-clinical/clinical and R&D expenses, and facility investment expenses."

Financing • CNS Disorders • Parkinson's Disease